Open access peer-reviewed chapter

The Use of Alginate Hydrogels for the Culture of Mesenchymal Stem Cells (MSCs): In Vitro and In Vivo Paradigms

Written By

Michail E. Klontzas, Hicham Drissi and Athanasios Mantalaris

Submitted: March 26th, 2019 Reviewed: June 12th, 2019 Published: July 24th, 2019

DOI: 10.5772/intechopen.88020

Chapter metrics overview

1,113 Chapter Downloads

View Full Metrics


Alginate hydrogels have been widely used in stem cell cultures due to their biocompatibility, malleable nature, high water content, enhanced mass transport properties, and their functionalization with bioactive molecules providing cues that modulate cell proliferation and differentiation. Mesenchymal stem cells (MSCs) are extensively utilized in clinical cellular therapies because of their differentiation efficiency, their immunosuppressive properties, and them not being tumorigenic when implanted in vivo. MSCs are isolated from numerous fetal and adult tissues, suitable for both autologous and allogeneic applications. Consequently, alginate hydrogels/MSCs have been applied in vivo for the treatment of a wide variety of musculoskeletal, cardiac, neural, and endocrine disorders. This chapter will review the use of alginate hydrogels (physical properties and functionalization) for MSC culture in vitro (various culture systems) and the application of alginate/MSC implants (animal models and human applications) for cellular therapy purposes in vivo.


  • alginate
  • mesenchymal stem cells
  • MSCs
  • in vivo
  • in vitro
  • hydrogels

1. Introduction

Alginate has been extensively used for tissue engineering and regenerative medicine purposes [1]. Its ability to form hydrogels under mild gelation conditions in the presence of ions such as Ca2+, Ba2+, and Sr2+ renders it suitable for cell-based applications where exposure to harsh crosslinking buffers can lead to cell damage. When alginate is exposed to a crosslinking solution, l-guluronic residues of adjacent polysaccharide strands are connected forming a hydrogel [2, 3]. Alginate hydrogels possess the advantages of natural biomaterials such as excellent biocompatibility and abundance in nature with a low cost, properties which render it an excellent candidate for cell-based regenerative medicine applications [4]. However, the lack of alginate bioactivity requires functionalization with a wide variety of molecules promoting adhesion and modulation of stem cell fate. The purpose of this chapter is to provide an overview of the use of alginate hydrogels with mesenchymal stem cells (MSCs) which represent one of the most widely used stem cell type and the only stem cell type currently in clinical use.


2. Mesenchymal stem cells (MSCs) for tissue engineering

MSCs are multipotent stem cells with the ability to proliferate and differentiate into a variety of mature cells, mainly osteocytes, chondrocytes, and adipocytes [5].

MSCs can be isolated from a multitude of adult and fetal tissues including but not limited to the bone marrow, adipose tissue, peripheral blood, synovial tissue, placenta, Wharton’s jelly, and umbilical cord blood. Importantly, it has been shown that MSCs isolated from different tissue sources possess differential proliferation and differentiation capacity toward various lineages [6] (Figure 1). Since their description by Friedenstein et al. [7], MSCs have been evolved as the stem cell type with the most regenerative medicine applications and the only stem cell type used in clinic to date.

Figure 1.

Tissue sources and properties of mesenchymal stem cells.

MSCs represent attractive stem cell candidates for the use in tissue engineering and regenerative medicine applications for a variety of reasons. Firstly, they have the ability to proliferate and differentiate producing tissues, which are clinically relevant for regenerative medicine purposes such as musculoskeletal and neural tissues. In addition, they offer the possibility of autologous use, which can avoid adverse immune responses to allogeneic cells while also possessing an immunomodulatory capacity being able to regulate the immune environment even when implanted in an allogeneic fashion. Finally, the use of MSCs avoids the ethical shortcomings of embryonic stem cell (ESC) use and is not associated with the formation of teratomas which is a characteristic of pluripotent stem cell implantation (ESCs and induced pluripotent stem cells—iPSCs) [8, 9, 10]. Recently, protocols for the derivation of MSCs from iPSCs have also enabled the production of unlimited MSC numbers by exploiting the unlimited proliferation capacity of iPSCs prior to their differentiation to MSCs [11, 12, 13].

The use of MSCs for tissue engineering and regenerative medicine purposes requires the robust characterization of MSCs at several levels. At the moment, the International Society for Cell and Gene Therapy (ISCT) has posed the minimal criteria that need to be fulfilled so that a cell population is characterized as MSCs. These include the adherence to plastic; the presence (≥95%) of surface markers including CD73, CD90, and CD105; and the absence (≤2%) of hematopoietic markers (CD34, CD45, CD79a or CD19, CD14 or CD11b, and HLA II). Finally, cells characterized as MSCs should possess the capacity to differentiate to osteoblasts, chondroblasts, and adipocytes in vitro [14]. Other surface markers have been utilized over the years for the characterization of MSCs including Stro-1, CD271, CD146, and MSCA-1, but their use has not yet been established as a routine for MSC research [15, 16, 17, 18]. Recently, omics strategies have emerged as promising alternatives for the comprehensive evaluation of MSC quality at the undifferentiated and differentiated states [11, 19, 20, 21, 22, 23].


3. The use of alginate hydrogels and MSCs in tissue engineering and regenerative medicine applications

Due to the lack of bioactive molecules on the alginate structure, alginate hydrogels used for cell-based applications require functionalization with molecules which can aid cell adhesion, increase cellular proliferation, and/or guide stem cell differentiation toward the desired cell lineages. In an attempt to increase cell adhesion on alginate hydrogels, a wide variety of extracellular matrix proteins or protein fragments have been employed. The most commonly used molecules include collagen, gelatin (product of collagen hydrolysis), and arginylglycylaspartic acid (RGD) peptide, which is the functional adhesion sequence in several extracellular matrix (ECM) proteins. Gelatin has been widely utilized for the enhancement of cell adhesion and differentiation in alginate hydrogels [24] either mixed [25] or crosslinked with alginate [26]. It has also been shown that crosslinking of alginate with gelatin reduces gelatin leak over prolonged culture while enhancing cell adhesion and vascular endothelial growth factor (VEGF) secretion compared to natural alginate and RGD-alginate [27].

Oxidized alginate has been widely used for tissue engineering purposes. Alginate can be oxidized with the use of agents including sodium permanganate (KMnO4) and periodate, to produce two free aldehyde groups on the alginate backbone, offering enhanced in vitro and in vivo. Alginate oxidation is necessitated by the lack of natural alginate degrading enzymes in mammals, which is translated to a slower biodegradation of alginate hydrogels [28, 29]. Additionally, free aldehyde groups offer sites for possible crosslinking with amine group-containing molecules, which can be used for the robust functionalization of hydrogels used for tissue engineering [29, 30]. Similarly to natural alginate, a wide range of biomolecules have been used for the functionalization of oxidized alginate. The most commonly used are gelatin and RGD, which have been shown promote cell adhesion and viability [31] .

3.1 In vitro paradigms of alginate/MSC constructs

Culture of MSCs in alginate hydrogels has been attempted for applications ranging from the regeneration of bone, cartilage, and tendon to the repair of damaged myocardium and trachea. Most of the initial data on the use of alginate/MSC constructs have been obtained in vitro (Table 1).

First author [reference]YearType of hydrogelMSC type
Park Y [43]2005AlginateSynovial MSCs
Coates EE [42]2013Methacrylated alginate-HABone marrow MSCs
Tohamy KM [45]2018Sodium alginate (SA)/hydroxyethylcellulose (HEC)/hydroxyapatite (HA)Bone marrow MSCs
Yeatts A [60]2011AlginateBone marrow MSCs
Wang M [61]2016Alginate-HABone marrow MSCs
Chen B [56]2013Strontium crosslinked alginateBone marrow MSCs
Weber M [41]***2002AlginateC3H10T1/2 MSC cell line
Hsu S [50]2011Alginate/nano-sized calcium-deficient hydroxyapatite/RGDPlacental MSCs and bone marrow MSCs
Schütz K [58]2017Alginate/methylcelluloseBone marrow MSCs
Kolambkar Y [64]2007AlginateAmniotic fluid MSCs
Liu J [33]2012Alginate-fibrin-RGDUmbilical cord MSCs
Du W-J [65]2016Alginate-HABone marrow and adipose MSCs
Straccia M [66]2015Alginate-chitosanBone marrow MSCs
Maia F [35]2014Alginate-RGDBone marrow MSCs
Huang J [59]2016Alginate-gelatin-carboxymethyl chitosanBone marrow MSCs
Karunanithi P [38]2016Alginate-fucoidanBone marrow MSCs
Klontzas ME [20]2019Oxidized alginate-GHKUmbilical cord blood MSCs
Jose S [39]2014Alginate-GHKBone marrow MSCss
Sarker B [53]2017Oxidized alginate-gelatinAdipose tissue MSCs
Bernhardt A [46]2009Alginate-gelatin-HABone marrow MSCs
Wang Y [47]2014Oxidized alginate-gelatin-N-succinyl chitosanBone marrow MSCs
Zhao L [48]2010Alginate-calcium phosphateUmbilical cord MSCs
Zhou H [49]2011Alginate-fibrinUmbilical cord MSCs

Table 1.

Representative in vitro studies combining alginate-based hydrogels with MSCs.

Functionalization of alginate has been achieved with molecules mimicking the ECM, the most commonly used of which are RGD and gelatin. RGD has been used to increase adhesion in photo cross-linked alginate hydrogels which were found to maintain viability and promote proliferation of bone marrow MSCs [32] and muscle differentiation of umbilical cord MSCs in alginate-fibrin hydrogels [33]. Tyramine has been also cross-linked to alginate to increase MSC adhesion [34]. In hydrogels functionalized with RGD, it has been shown that high cell density favors cell-cell contact and promotes osteogenic differentiation [35] as well as increasing survival and VEGF secretion from MSC spheroids [36]. The combination of RGD with a matrix metalloproteinase cleavable peptide (proline-valine-glycine-leucine-isoleucine-glycine) in alginate has been shown to promote adhesion and allow better elongation of MSCs than RGD alginate [37]. Increased chondrogenesis has been also demonstrated with the incorporation of fucoidan (a heparan sulfate analogue) in alginate hydrogels seeded with bone marrow MSCs [38]. Glycine-histidine-lysine (GHK), a tripeptide fragment 0f osteonectin (a bone ECM protein), has been cross-linked with natural alginate and oxidized alginate achieving enhanced VEGF secretion from bone marrow MSCs [39] and increased osteogenic differentiation of umbilical cord blood MSCs compared to oxidized alginate with gelatin [20]. Finally, functionalization of alginate with RGD has been shown to promote adipose tissue MSC chondrogenesis via integrin-dependent transforming growth factor (TGF)-β3 activation [40].

One of the most common applications of alginate/MSC constructs is for cartilage tissue engineering. It has been shown that cells differentiated to chondroblasts in alginate hydrogels produce more collagen type II than in monolayer where they predominantly produce collagen type I [41]. In addition, photocrosslinked alginate/hyaluronic acid injectable hydrogels have been shown to support the chondrogenic differentiation of bone marrow MSCs for cartilage tissue engineering [42]. Alginate hydrogels have been also combined with synovial MSCs showing chondrogenic gene expression and collagen type II deposition under the effect of bone morphogenetic protein-2 (BMP-2). However, the authors noted that full progression of chondrogenesis was not feasible [43]. Interestingly enough when applied to bone marrow MSCs in RGD-alginate hydrogels, BMP-2 has promoted osteogenic differentiation showing that it favors osteogenic differentiation [44].

Several studies have demonstrated the suitability of alginate hydrogels in combination with MSCs for bone tissue engineering. Sodium alginate (SA)/hydroxyethylcellulose (HEC)/hydroxyapatite (HA) hydrogels have been combined with bone marrow MSCs for bone tissue engineering maintaining high cell viability and proliferation [45]. Alginate-gelatin-hydroxyapatite [46] and oxidized alginate-gelatin-N-succinyl chitosan hydrogels [47] have been shown to promote the osteogenic differentiation of bone marrow MSCs. Injectable hydrogels have been also tested for the repair of bone defects such as alginate-calcium phosphate [48] and alginate-fibrin hydrogels [49] combined with umbilical cord MSCs. Such materials enable the direct injection of the hydrogel paste in a bone defect and have been shown to promote osteogenic differentiation of MSCs facilitating fracture healing. Hydroxyapatite (calcium-deficient) and RGD have also been combined with alginate for cartilage regeneration showing that placental MSCs could perform better chondrogenesis than bone marrow MSCs [50]. However, RGD-functionalized alginate has been also shown to enhance osteogenic differentiation, mineralization, and viability [51, 52]. Oxidized alginate hydrogels have been also widely utilized for bone tissue engineering. It has been cross-linked with fibrin achieving high cell viability and osteogenic differentiation of Wharton’s jelly MSCs compared to plain natural and oxidized alginate [49]. Sarker and co-workers have described the crosslinking of oxidized alginate with gelatin hydrogels for bone regeneration, demonstrating enhanced osteogenesis of adipose tissue and increase of VEGF secretion from MG-63 osteosarcoma cells compared to plain alginate and RGD-functionalized alginate [27, 53]. Other groups have also confirmed the suitability of oxidized alginate for the osteogenic differentiation of adipose-derived MSCs [53] and muscle differentiation of Wharton’s jelly MSCs [54].

Apart from bone and cartilage regeneration, alginate hydrogels have found a limited number of other applications such as the regeneration of nucleus pulposus of the intervertebral disk, the cryopreservation of MSCs, and the three-dimensional printing of cellularized structures. Specifically, alginate hydrogels outperform chitosan hydrogels in glycosaminoglycan deposition and the production of collagen type II for nucleus pulposus engineering [55]. In addition, they have been used for the cryopreservation of MSCs avoiding minimizing the effects of freezing and thawing on stem cell viability [56], and various formulations of alginate such as oxidized alginate-gelatin [57], alginate/methylcellulose [58], and alginate-gelatin-carboxymethyl chitosan [59] have been found to be suitable for 3D printing applications.

Finally, it should be mentioned that there is a constantly increasing use of dynamic bioreactor cultures for the cultivation of alginate/MSC constructs. For example, dynamic perfusion bioreactor cultures of bone marrow MSCs in alginate hydrogels have been shown to enhance early in vitro osteogenic commitment and late osteogenesis [60, 61], and dynamic cultures incorporating compression forces have been used for chondrogenic differentiation purposes [62].

Despite the encouraging in vitro results, it needs to be noted that in vitro data do not necessarily correlate to the efficiency of hydrogels in vivo. As shown by Yang et al. who performed a direct in vitro-in vivo comparison of differentiation in alginate-gelatin hydrogels with MSCs, subcutaneous implantation in mice inhibits tri-lineage differentiation despite the efficient in vitro differentiation [63]. These results highlight the fact that caution is needed when extrapolating in vitro results to the in vivo setting.

3.2 In vivo paradigms of alginate/MSC constructs

Various types of alginate hydrogels have been shown to promote bone healing in animal models (Table 2). Injectable materials such as chitosan-alginate-BMP-2 and alginate-hydroxyapatite (HA)-mineralized microsphere combinations have been used in conjunction with MSCs to promote bone healing in vivo, demonstrating the efficient formation of trabecular bone [67, 68]. When used for bone tissue engineering, alginate hydrogels are usually seeded with MSCs and are allowed to gradually obtain higher mechanical stability as a result of ECM deposition and mineralization. However, tough alginate hydrogels have been also developed in order to achieve high mechanical stability which has been shown to promote bone healing [69]. Additionally, animal experiments have shown that when RGD is used for alginate modification, faster stress relaxation of alginate hydrogels [70] and high peptide density are linked to more efficient osteogenic differentiation than low peptide density which was linked to cell migration [71]. This correlates with results showing that increasing RGD concentrations inhibit chondrogenic differentiation in vitro [72]. Rottensteiner et al. utilized oxidized alginate-gelatin-nano-Bioglass hydrogels for bone regeneration identifying evidence of in vivo vascularization without adverse reactions, despite the cytotoxic action of Bioglass in vitro [73]. Additionally, Paul et al. successfully treated critical size calvarial defects with serum-loaded oxidized alginate-gelatin-biphasic calcium phosphate hydrogels with rat BM MSCs [74]. Importantly, encapsulation of MSCs in oxidized and natural alginate hydrogels increases vascularization which is of utmost importance in bone tissue engineering and the repair of vascular lesions [75] such as hind limb ischemia [76].

First author [reference]YearType of hydrogelMSC typeApplication
Zhang F [81]2012AlginateCo-culture of synovial MSCs with transgenic chondrocytesCartilage regeneration
Yu J [85]2010Alginate-RGDBone marrow MSCsMyocardial regeneration
Yang C [63]2009Alginate-gelatin porous scaffoldsBone marrow MSCsRegeneration of multiple tissues
Leijs M [91]2017AlginateBone marrow MSCsInflammatory diseases
Steiner D [92]2018Oxidized alginate-gelatinBone marrow MSCsVascularization
Wang S [90]2016AlginateUmbilical cord MSCsSkin wound healing
Rottensteiner [73]2014Oxidized alginate with nano-Bioglass®Bone marrow MSCsBone regeneration
Chung J [77]2014Alginate combined with pluronic, HA, and chitosanUmbilical cord bloodCartilage regeneration
Re’em T [84]2012Alginate with TGF-β1Bone marrow MSCsCartilage regeneration
Sondermeijer H [86]2018Alginate-cyclic RGDBone marrow MSCsCardiac regeneration
Park D [67]2005Alginate-chitosan-BMP-2Bone marrow MSCsBone regeneration
Schon LC [88]2014AlginateBone marrow MSCsTendon regeneration
Hashemibeni B [80]2012AlginateAdipose MSCs and chondrocytesTracheal repair
Ho SS [93]2016Oxidized methacrylated alginate-RGDBone marrow MSCsBone regeneration
Moshaverinia A [89]2014RGD-alginate with TGF-β3Gingival and periodontal MSCsTendon regeneration
Ingavle GC [68]2019Alginate-HA-mineralized microspheresBone marrow MSCsBone regeneration

Table 2.

Representative in vivo studies combining alginate-based hydrogels with MSCs.

The ability of alginate hydrogels with MSCs to repair cartilage defects in animal models has been demonstrated in a variety of studies with various MSC types and hydrogel formulations. Chung et al. have compared a variety of hydrogel formulations including alginate, HA, chitosan, pluronic, and combinations of them seeded with umbilical cord blood MSCs. Their results demonstrated that even though alginate mixed with pluronic and chitosan achieved a certain degree of healing in rat knee cartilage defects, it was 4% hyaluronic acid which resulted in the optimal cartilage repair with macroscopic and microscopic appearance of adjacent healthy cartilage [77]. High-quality repair of in vivo rabbit cartilage defects has been shown with the use of bone marrow MSCs and natural alginate [78]. Alginate has been also combined with polylactic acid to promote in vivo cartilage repair with bone marrow MSCs [79]. In vivo cartilage differentiation in alginate hydrogels has been also attempted for the repair of tracheal tissue with the combination of adipose tissue MSCs and chondrocytes [80]. Synovial MSCs have also been co-cultured with chondrocytes transgenic for TGF-β3 in alginate hydrogels, demonstrating that TGF-β3 release can induce synovial MSC chondrogenesis [81]. The simultaneous activation of TGF-β3 and BMP-2 genes in MSC laden alginate hydrogels showed superior chondrogenesis compared to the isolated delivery of each one of the factors where cells progressed to endochondral osteogenesis instead of chondrogenesis [82]. Interestingly, alginate was found more capable in promoting endochondral osteogenesis than chondrogenesis when compared to chitosan [83]. Finally, TGF-β1-releasing alginate hydrogels have been used to promote chondrogenesis of MSCs, demonstrating in vitro increase of chondrogenic markers and healing of articular cartilage defects in mice [84].

Another important application of alginate/MSC constructs is the treatment of myocardial lesions. Yu et al. combined RGD-functionalized alginate hydrogels with human bone marrow MSCs showing that they could improve left ventricular function after myocardial infarction in a rat acute myocardial infarction model [85]. Cyclic RGD in alginate hydrogels has been also shown to promote neoangiogenesis and cardiac neovascularization, improving cardiac function in animals post-myocardial infarction [86]. Finally, when alginate hydrogels are used for cardiac regeneration, it has been shown that G-type alginates possess properties suited for the regeneration of cardiac tissue [87].

MSCs have been combined with alginate hydrogels for tendon repair purposes in animal model of tendon tears. For example, rat Achilles tendon lesions have been treated with hydrogels loaded with MSCs [88] showing healing of higher quality than surgical meshes and sutures. In addition, RGD-functionalized hydrogels loaded with TGF-β3 and loaded with periodontal and gingival MSCs were found to efficiently produce tendon tissue when implanted subcutaneously in mice [89].

Alginate hydrogels have also been widely utilized as wound dressings either alone or in combination with MSCs. For this application, various types of MSCs have been used including umbilical cord MSCs [90] and bone marrow MSCs in alginate-chitosan hydrogels with antibacterial properties [66].

Finally, alginate hydrogels have been used to protect MSCs from the local immune response elicited when allogeneic cells are implanted in vivo. They have been shown to provide protection from the immune system increasing the survival of MSCs in the hostile environment of the host-releasing immunomodulatory factors [91].


4. Conclusions

In conclusion, alginate/MSC constructs have been used for a wide variety of regenerative medicine applications, ranging from musculoskeletal to cardiac tissue repair. MSCs isolated from adult and fetal tissues have been combined with alginate hydrogels functionalized with extracellular matrix components, minerals, and other natural polymers and evaluated in vitro and in vivo. In vitro studies demonstrated the ability of alginate hydrogel at different formulations to support MSC growth and differentiation toward several lineages, whereas in vivo data have shown that when alginate-based materials are combined with MSCs, they can achieve successful healing of bone and cartilage defects, myocardial tissue after myocardial infarction, tendon tears, and skin wound. Nonetheless, evaluation of safety and efficacy of the constructs is required prior to clinical use. Existing in vitro and in vivo data demonstrate the potential of alginates to play an important future role in regenerative medicine, reaching the bedside and achieving regeneration of damaged tissues.


Conflict of interest

The authors declare no conflict of interest.


  1. 1. Lee KY, Mooney DJ. Alginate: Properties and biomedical applications. Progress in Polymer Science. 2012;37:106-126
  2. 2. Sikorski P, Mo F, Skjåk-Bræk G, Stokke BT. Evidence for egg-box-compatible interactions in calcium-alginate gels from fiber X-ray diffraction. Biomacromolecules. 2007;8:2098-2103
  3. 3. Kühbeck D, Mayr J, Häring M, Hofmann M, Quignard F, Díaz Díaz D. Evaluation of the nitroaldol reaction in the presence of metal ion-crosslinked alginates. New Journal of Chemistry. 2015;39:2306-2315
  4. 4. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Advanced Materials. 2006;18:1345-1360
  5. 5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (80-). 1999;284:143-147
  6. 6. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Communication and Signaling. 2011;9:12
  7. 7. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology. 1976;4:267-274
  8. 8. Seong JM, Kim B-C, Park J-H, Kwon IK, Mantalaris A, Hwang Y-S. Stem cells in bone tissue engineering. Biomedical Materials. 2010;5:062001
  9. 9. Ma J, Both SK, Yang F, Cui F-Z, Pan J, Meijer GJ, et al. Concise review: Cell-based strategies in bone tissue engineering and regenerative medicine. Stem Cells Translational Medicine. 2014;3:98-107
  10. 10. Klontzas ME, Kenanidis EI, Heliotis M, Tsiridis E, Mantalaris A. Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells. Expert Opinion on Biological Therapy. 2015;15:1541-1552
  11. 11. Devito L, Klontzas ME, Cvoro A, Galleu A, Simon M, Hobbs C, et al. Comparison of human isogeneic Wharton’s jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulation. Cell Death & Disease. 2019;10:1-13
  12. 12. Lian Q , Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121:1113-1123
  13. 13. Zhao Q , Gregory CA, Lee RH, Reger RL, Qin L, Hai B, et al. MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:530-535
  14. 14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position Statement, Cytotherapy. 2006;8:315-317
  15. 15. Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, De Zwart P, et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 2009;94:173-184
  16. 16. Gothard D, Greenhough J, Ralph E, Oreffo RO. Prospective isolation of human bone marrow stromal cell subsets: A comparative study between Stro-1-, CD146- and CD105-enriched populations. Journal of Tissue Engineering. 2014;5:1-17
  17. 17. Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Annals of the New York Academy of Sciences. 2007;1106:262-271
  18. 18. Bosch J, Houben AP, Radke TF, Stapelkamp D, Bünemann E, Balan P, et al. Distinct differentiation potential of “MSC” derived from cord blood and umbilical cord: Are cord-derived cells true mesenchymal stromal cells? Stem Cells and Development. 2012;21:1977-1988
  19. 19. Wobma HM, Tamargo MA, Goeta S, Brown LM, Duran-Struuck R, Vunjak-Novakovic G. The influence of hypoxia and IFN-γ on the proteome and metabolome of therapeutic mesenchymal stem cells. Biomaterials. 2018;167:226-234
  20. 20. Klontzas ME, Reakasame S, Silva R, Morais JCF, Vernardis S, MacFarlane RJ, et al. Oxidized alginate hydrogels with the GHK peptide enhance cord blood mesenchymal stem cell osteogenesis: A paradigm for metabolomics-based evaluation of biomaterial design. Acta Biomaterialia. 2019;88:224-240
  21. 21. McNamara LE, Sjöström T, Meek RMD, Oreffo ROC, Su B, Dalby MJ, et al. Metabolomics: A valuable tool for stem cell monitoring in regenerative medicine. Journal of the Royal Society Interface. 2012;9:1713-1724
  22. 22. Kalajzic I, Staal A, Yang WP, Wu Y, Johnson SE, Feyen JHM, et al. Expression profile of osteoblast lineage at defined stages of differentiation. The Journal of Biological Chemistry. 2005;280:24618-24626
  23. 23. Klontzas ME, Vernardis SI, Heliotis M, Tsiridis E, Mantalaris A. Metabolomics analysis of the osteogenic differentiation of umbilical cord blood mesenchymal stem cells reveals differential sensitivity to osteogenic agents. Stem Cells and Development. 2017;26:723-733
  24. 24. Venkatesan J, Bhatnagar I, Manivasagan P, Kang K-H, Kim S-K. Alginate composites for bone tissue engineering: A review. International Journal of Biological Macromolecules. 2014;72:269-281
  25. 25. Hwang Y-S, Cho J, Tay F, Heng JYY, Ho R, Kazarian SG, et al. The use of murine embryonic stem cells, alginate encapsulation, and rotary microgravity bioreactor in bone tissue engineering. Biomaterials. 2009;30:499-507
  26. 26. Sarker B, Papageorgiou DG, Silva R, Zehnder T, Gul-E-Noor F, Bertmer M, et al. Fabrication of alginate–gelatin crosslinked hydrogel microcapsules and evaluation of the microstructure and physico-chemical properties. Journal of Materials Chemistry B. 2014;2:1470
  27. 27. Grigore A, Sarker B, Fabry B, Boccaccini AR, Detsch R. Behavior of encapsulated MG-63 cells in RGD and gelatine-modified alginate hydrogels. Tissue Engineering. Part A. 2014;20:2140-2150
  28. 28. Wang L, Shansky J, Borselli C, Mooney D, Vandenburgh H. Design and fabrication of a biodegradable, covalently crosslinked shape-memory alginate scaffold for cell and growth factor delivery. Tissue Engineering. Part A. 2012;18:2000-2007
  29. 29. Reakasame S, Boccaccini AR. Oxidized alginate-based hydrogels for tissue engineering applications: A review. Biomacromolecules. 2018;19:3-21
  30. 30. Balakrishnan B, Joshi N, Jayakrishnan A, Banerjee R. Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration. Acta Biomaterialia. 2014;10:3650-3663
  31. 31. Sarker B, Singh R, Silva R, Roether JA, Kaschta J, Detsch R, et al. Evaluation of fibroblasts adhesion and proliferation on alginate-gelatin crosslinked hydrogel. PLoS One. 2014;9:e107952
  32. 32. Jeon O, Alsberg E. Photofunctionalization of alginate hydrogels to promote adhesion and proliferation of human mesenchymal stem cells. Tissue Engineering. Part A. 2013;19:1424-1432
  33. 33. Liu J, Zhou H, Weir MD, Xu HHK, Chen Q , Trotman CA. Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate. Tissue Engineering. Part A. 2012;18:2303-2314
  34. 34. Schulz A, Gepp MM, Stracke F, Von Briesen H, Neubauer JC. Tyramine-conjugated alginate hydrogels as a platform for bioactive scaffolds. Journal of Biomedical Materials Research. Part A. 2019;107A:114-121
  35. 35. Maia FR, Lourenc AH, Granja PL, Gonc RM, Barrias CC. Effect of cell density on mesenchymal stem cells aggregation in RGD-alginate 3D matrices under osteoinductive conditions. Macromolecular Bioscience. 2014;14:759-771
  36. 36. Ho SS, Murphy KC, Binder BYK, Vissers CB, Leach JK. Increased survival and function of mesenchymal stem cell spheroids entrapped in instructive alginate hydrogels. Stem Cells Translational Medicine. 2016;5:773-781
  37. 37. Fonseca KB, Bidarra SJ, Oliveira MJ, Granja PL, Barrias CC. Molecularly designed alginate hydrogels susceptible to local proteolysis as three-dimensional cellular microenvironments. Acta Biomaterialia. 2011;7:1674-1682
  38. 38. Karunanithi P, Murali MR, Samuel S, Raghavendran HRB, Abbas AA, Kamarul T. Three dimensional alginate-fucoidan composite hydrogel augments the chondrogenic differentiation of mesenchymal stromal cells. Carbohydrate Polymers. 2016;147:294-303
  39. 39. Jose S, Hughbanks ML, Binder BYK, Ingavle GC, Leach JK. Enhanced trophic factor secretion by mesenchymal stem/stromal cells with Glycine-Histidine-Lysine (GHK)-modified alginate hydrogels. Acta Biomaterialia. 2014;10:1955-1964
  40. 40. Chang JC, Hsu SH, Chen DC. The promotion of chondrogenesis in adipose-derived adult stem cells by an RGD-chimeric protein in 3D alginate culture. Biomaterials. 2009;30:6265-6275
  41. 41. Weber M, Steinert A, Jork A, Dimmler A, Thürmer F, Schütze N, et al. Formation of cartilage matrix proteins by BMP-transfected murine mesenchymal stem cells encapsulated in a novel class of alginates. Biomaterials. 2002;23:2003-2013
  42. 42. Coates EE, Riggin CN, Fisher JP. Photocrosslinked alginate with hyaluronic acid hydrogels as vehicles for mesenchymal stem cell encapsulation and chondrogenesis. Journal of Biomedical Materials Research. Part A. 2013;101A:1962-1970
  43. 43. Park Y, Sugimoto M, Watrin A, Chiquet M, Hunziker EB. BMP-2 induces the expression of chondrocyte-specific genes in bovine synovium-derived progenitor cells cultured in three-dimensional alginate hydrogel. Osteoarthritis and Cartilage. 2005;13:527-536
  44. 44. Jung T, Lee JH, Park S, Kim Y, Seo J, Shim H, et al. Effect of BMP-2 delivery mode on osteogenic differentiation of stem cells. Stem Cells International. 2017;7859184:1-7
  45. 45. Tohamy KM, Mabrouk M, Soliman IE, Beherei HH, Aboelnasr MA. Novel alginate/hydroxyethyl cellulose/hydroxyapatite composite scaffold for bone regeneration: In vitro cell viability and proliferation of human mesenchymal stem cells. International Journal of Biological Macromolecules. 2018;112:448-460
  46. 46. Bernhardt A, Despang F, Lode A, Demmler A, Hanke T, Gelinsky M. Proliferation and osteogenic differentiation of human bone marrow stromal cells on alginate-gelatine-hydroxyapatite scaffolds with anisotropic pore structure. Journal of Tissue Engineering and Regenerative Medicine. 2009;3:54-62
  47. 47. Wang Y, Peng W, Liu X, Zhu M, Sun T, Peng Q , et al. Study of bilineage differentiation of human-bone-marrow-derived mesenchymal stem cells in oxidized sodium alginate/N-succinyl chitosan hydrogels and synergistic effects of RGD modification and low-intensity pulsed ultrasound. Acta Biomaterialia. 2014;10:2518-2528
  48. 48. Zhao L, Weir MD, Xu HHK. An injectable calcium phosphate-alginate hydrogel-umbilical cord mesenchymal stem cell paste for bone tissue engineering. Biomaterials. 2010;31:6502-6510
  49. 49. Zhou H, Xu HHK. The fast release of stem cells from alginate-fibrin microbeads in injectable scaffolds for bone tissue engineering. Biomaterials. 2011;32:7503-7513
  50. 50. Hsu S-H, Huang T-B, Cheng S-J, Weng S-Y, Tsai C-L, Tseng C-S, et al. Chondrogenesis from human placenta-derived mesenchymal stem cells in three-dimensional. Tissue Engineering. Part A. 2011;17:1549-1560
  51. 51. Evangelista MB, Hsiong SX, Fernandes R, Sampaio P, Kong HJ, Barrias CC, et al. Upregulation of bone cell differentiation through immobilization within a synthetic extracellular matrix. Biomaterials. 2007;28:3644-3655
  52. 52. Bidarra SJ, Barrias CC, Barbosa MA, Soares R, Granja PL. Immobilization of human mesenchymal stem cells within RGD-grafted alginate microspheres and assessment of their angiogenic potential. Biomacromolecules. 2010;11:1956-1964
  53. 53. Sarker B, Zehnder T, Rath SN, Horch RE, Kneser U, Detsch R, et al. Oxidized alginate-gelatin hydrogel: A favorable matrix for growth and osteogenic differentiation of adipose-derived stem cells in 3D. ACS Biomaterials Science & Engineering. 2017;3:1730-1737
  54. 54. Baniasadi H, Mashayekhan S, Fadaoddini S, Haghirsharifzamini Y. Design, fabrication and characterization of oxidized alginate-gelatin hydrogels for muscle tissue engineering applications. Journal of Biomaterials Applications. 2016;31:152-161
  55. 55. Naqvi SM, Buckley CT. Differential response of encapsulated nucleus pulposus and bone marrow stem cells in isolation and coculture in alginate and chitosan hydrogels. Tissue Engineering. Part A. 2015;21:288-299
  56. 56. Chen B, Wright B, Sahoo R, Connon CJ. A novel alternative to cryopreservation for the short-term storage of stem cells for use in cell therapy using alginate encapsulation. Tissue Engineering Part C. 2013;19:568-576
  57. 57. Zehnder T, Sarker B, Boccaccini AR, Detsch R. Evaluation of an alginate-gelatine crosslinked hydrogel for bioplotting. Biofabrication. 2015;7:025001
  58. 58. Schütz K, Placht A, Paul B, Brüggemeier S, Gelinsky M. Three-dimensional plotting of a cell-laden alginate/methylcellulose blend: Towards biofabrication of tissue engineering constructs with clinically relevant dimensions. Journal of Tissue Engineering and Regenerative Medicine. 2017;11:1574-1587
  59. 59. Huang J, Fu H, Wang Z, Meng Q , Liu S, Wang H, et al. BMSCs-laden gelatin/sodium alginate/carboxymethyl chitosan hydrogel for 3D bioprinting. RSC Advances. 2016;6:108423-108430
  60. 60. Yeatts AB, Fisher JP. Tubular perfusion system for the long-term dynamic culture of human mesenchymal stem cells. Tissue Engineering Part C. 2011;17:337-348
  61. 61. Wang MO, Bracaglia L, Thompson JA, Fisher JP. Hydroxyapatite-doped alginate beads as scaffolds for the osteoblastic differentiation of mesenchymal stem cells. Journal of Biomedial Materials Research Part A. 2016;104A:2325-2333
  62. 62. Guo T, Lim CG, Goodley AS, Xiao X, Placone JK, Ferlin KM, et al. Effect of dynamic culture and periodic compression on human Mesenchymal stem cell proliferation and chondrogenesis. Annals of Biomedical Engineering. 2016;44:2103-2113
  63. 63. Yang C, Frei H, Rossi FM, Burt HM. The differential in vitro and in vivo responses of bone marrow stromal cells on novel porous gelatin–alginate scaffolds. Journal of Tissue Engineering and Regenerative Medicine. 2009;3:601-614
  64. 64. Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE. Chondrogenic differentiation of amniotic fluid-derived stem cells. Journal of Molecular Histology. 2007;38:405-413
  65. 65. Du W-J, Reppel L, Leger L, Schenowitz C, Huselstein C, Bensoussan D, et al. Mesenchymal stem cells derived from human bone marrow and adipose tissue maintain their immunosuppressive properties after chondrogenic differentiation. Stem Cells and Development. 2016;25:1454-1469
  66. 66. Straccia MC, D’Ayala GG, Romano I, Oliva A, Laurienzo P. Alginate hydrogels coated with chitosan for wound dressing. Marine Drugs. 2015;13:2890-2908
  67. 67. Park DJ, Choi BH, Zhu SJ, Huh JY, Kim BY, Lee SH. Injectable bone using chitosan-alginate gel/mesenchymal stem cells/BMP-2 composites. Journal of Cranio-Maxillofacial Surgery. 2005;33:50-54
  68. 68. Ingavle GC, Gionet-Gonzales M, Vorwald CE, Bohannon LK, Clark K, Galuppo LD, et al. Injectable mineralized microsphere-loaded composite hydrogels for bone repair in a sheep bone defect model. Biomaterials. 2019;197:119-128
  69. 69. Darnell MC, Sun JY, Mehta M, Johnson C, Arany PR, Suo Z, et al. Performance and biocompatibility of extremely tough alginate/polyacrylamide hydrogels. Biomaterials. 2013;34:8042-8048
  70. 70. Nam S, Stowers R, Lou J, Xia Y, Chaudhuri O. Varying PEG density to control stress relaxation in alginate-PEG hydrogels for 3D cell culture studies. Biomaterials. 2019;200:15-24
  71. 71. Ho SS, Keown AT, Addison B, Leach JK. Cell migration and bone formation from mesenchymal stem cell spheroids in alginate hydrogels are regulated by adhesive ligand density. Biomacromolecules. 2017;18:4331-4340
  72. 72. Connelly JT, García AJ, Levenston ME. Inhibition of in vitro chondrogenesis in RGD-modified three-dimensional alginate gels. Biomaterials. 2007;28:1071-1083
  73. 73. Rottensteiner U, Sarker B, Heusinger D, Dafinova D, Rath SN, Beier JP, et al. In vitro and in vivo biocompatibility of alginate dialdehyde/gelatin hydrogels with and without nanoscaled bioactive glass for bone tissue engineering applications. Materials (Basel). 2014;7:1957-1974
  74. 74. Paul K, Linh NTB, Kim BR, Sarkar SK, Choi HJ, Bae SH, et al. Effect of rat bone marrow derived-stem cell delivery from serum-loaded oxidized alginate-gelatin-biphasic calcium phosphate hydrogel for bone tissue regeneration using a nude mouse critical-sized calvarial defect model. Journal of Bioactive and Compatible Polymers. 2015;30:188-208
  75. 75. Steiner D, Lingens L, Fisher L, Kohn K, Detsch R, Boccaccini AR, et al. Encapsulation of mesenchymal stem cells improves vascularization of alginate-based scaffolds. Tissue Engineering. Part A. 2018;24:1320-1331
  76. 76. Landázuri N, Levit RD, Joseph G, Ortega-legaspi JM, Flores CA, Weiss D, et al. Alginate microencapsulation of human mesenchymal stem cells as a strategy to enhance paracrine-mediated vascular recovery after hindlimb ischaemia. Journal of Tissue Engineering and Regenerative Medicine. 2016;10:222-232
  77. 77. Chung JY, Song M, Ha C-W, Kim J-A, Lee C-H, Park Y-B. Comparison of articular cartilage repair with different hydrogel-human umbilical cord blood-derived mesenchymal stem cell composites in a rat model. Stem Cell Research & Therapy. 2014;5:39
  78. 78. Dashtdar H, Rothan HA, Tay T, Ahmad RE, Ali R, Tay LX, et al. A preliminary study comparing the use of allogenic chondrogenic pre-differentiated and undifferentiated mesenchymal stem cells for the repair of full thickness articular cartilage defects in rabbits. Journal of Orthopaedic Research. 2011;29:1336-1342
  79. 79. Wayne JS, McDowell CL, Shields KJ, Tuan RS. In vivo response of polylactic acid-alginate scaffolds and bone marrow-derived cells for cartilage tissue engineering. Tissue Engineering. 2005;11:953-963
  80. 80. Hashemibeni B, Goharian V, Esfandiari E, Sadeghi F, Fasihi F, Alipur R, et al. An animal model study for repair of tracheal defects with autologous stem cells and differentiated chondrocytes from adipose-derived stem cells. Journal of Pediatric Surgery. 2012;47:1997-2003
  81. 81. Zhang F, Su K, Fang Y, Sandhya S, Wang D-A. A mixed co-culture of mesenchymal stem cells and transgenic chondrocytes in alginate hydrogel for cartilage tissue engineering. Journal of Tissue Engineering and Regenerative Medicine. 2015;9:77-84
  82. 82. Gonzalez-fernandez T, Tierney EG, Cunniffe GM, O’Brien FJ, Kelly DJ. Gene delivery of TGF-b3 and BMP2 in an MSC-laden alginate hydrogel for articular cartilage and endochondral bone tissue engineering. Tissue Engineering. Part A. 2016;22:776-787
  83. 83. Sheehy EJ, Mesallati T, Vinardell T, Kelly DJ. Engineering cartilage or endochondral bone: A comparison of different naturally derived hydrogels. Acta Biomaterialia. 2015;13:245-253
  84. 84. Re’em T, Kaminer-Israeli Y, Ruvinov E, Cohen S. Chondrogenesis of hMSC in affinity-bound TGF-beta scaffolds. Biomaterials. 2012;33:751-761
  85. 85. Yu J, Du KT, Fang Q , Gu Y, Mihardja SS, Sievers RE, et al. The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials. 2010;31:7012-7020
  86. 86. Sondermeijer HP, Witkowski P, Seki T, Van Der Laarse A, Itescu S, Hardy MA. RGDfK-peptide modified alginate scaffold for cell. Tissue Engineering. Part A. 2018;24:740-751
  87. 87. Ceccaldi C, Fullana SG, Alfarano C, Lairez O, Calise D, Cussac D, et al. Alginate scaffolds for mesenchymal stem cell cardiac therapy: Influence of alginate composition. Cell Transplantation. 2012;21:1969-1984
  88. 88. Schon LC, Gill N, Thorpe M, Davis J, Nadaud J, Kim J, et al. Efficacy of a mesenchymal stem cell loaded surgical mesh for tendon repair in rats. Journal of Translational Medicine. 2014;12:1-9
  89. 89. Moshaverinia A, Xu X, Chen C, Ansari S, Zadeh HH, Snead ML, et al. Application of stem cells derived from the periodontal ligament or gingival tissue sources for tendon tissue regeneration. Biomaterials. 2014;35:2642-2650
  90. 90. Wang S, Yang H, Tang Z, Long G, Huang W. Wound dressing model of human umbilical cord mesenchymal stem cells-alginates complex promotes skin wound healing by paracrine signaling. Stem Cells International. 2016;3269267:1-8
  91. 91. Leijs MJC, Villafuertes E, Haeck JC, Koevoet WJLM, Fernandez-Gutierrez B, Hoogduijn MJ, et al. Encapsulation of allogeneic mesenchymal stem cells in alginate extends local presence and therapeutic function. European Cells & Materials. 2017;33:43-58
  92. 92. Steiner D, Lingens L, Fischer L, Köhn K, Detsch R, Boccaccini AR, et al. Encapsulation of mesenchymal stem cells improves vascularization of alginate-based scaffolds. Tissue Engineering Part A. 2018;24:1320-1331
  93. 93. Ho SS, Vollmer NL, Refaat MI, Jeon O, Alsberg E, et al. Bone morphogenetic protein-2 promotes human mesenchymal stem cell survival and resultant bone formation when entrapped in photocrosslinked alginate hydrogels. Advanced Healthcare Materials. 2016;5:2501-2509

Written By

Michail E. Klontzas, Hicham Drissi and Athanasios Mantalaris

Submitted: March 26th, 2019 Reviewed: June 12th, 2019 Published: July 24th, 2019